Table 1. Clinical characteristics and... | American Society of Hematology

Table 1.

Clinical characteristics and HLA-A, HLA-B, HLA-C, and HLA-DR genotypes of the patients participating in this study

Patient no.	Ig subtype	Clinical stage†	Disease phase	HLA-ABC	HLA-DR
1	IgG1κ	IIA	Untreated	A1, A2, B12(44), B15(62)	DR4
2	IgG1λ	IIA	Stable PR‡	A1, A28, B8, B12(44), Cw5, Cw7	DR3(17), DR4
3	IgG1κ	IIA	Stable PR‡	A02, A24, B07, B15, C07, C12	DRB111, DRB115
4	IgG1λ	IIA	Untreated	A2, A11, B7, B35, Bw6, Cw4, Cw6	DR3(17)
5	IgGκ	IA	Untreated	A3, A19(32), B7, B40(60), Bw6, Cw3, Cw7	DR2(15), DR4

Patient no.	Ig subtype	Clinical stage†	Disease phase	HLA-ABC	HLA-DR
1	IgG1κ	IIA	Untreated	A1, A2, B12(44), B15(62)	DR4
2	IgG1λ	IIA	Stable PR‡	A1, A28, B8, B12(44), Cw5, Cw7	DR3(17), DR4
3	IgG1κ	IIA	Stable PR‡	A02, A24, B07, B15, C07, C12	DRB111, DRB115
4	IgG1λ	IIA	Untreated	A2, A11, B7, B35, Bw6, Cw4, Cw6	DR3(17)
5	IgGκ	IA	Untreated	A3, A19(32), B7, B40(60), Bw6, Cw3, Cw7	DR2(15), DR4

According to Durie and Salmon.¹⁵

Unmaintained partial remission and plateau phase for 1 to 3 years.